IL-NIQ
19.9.2023 15:01:43 CEST | Business Wire | Press release
NIQ, the global leader in consumer intelligence, is pleased to announce the NIQ Connect platform capabilities have now expanded to use Snowflake Secure Data Sharing. This capability marks a significant milestone for NIQ's Connect platform, empowering customers in 84 global markets with enhanced data-sharing capabilities and seamless real-time data access. As a result, this can eliminate processing and loading wait times, delivering unparalleled efficiency and agility in a complex consumer landscape.
“By extending their ability to effortlessly access global, omnichannel data, we can empower clients to uncover new pathways to growth even within a very complex consumer landscape,” said Troy Treangen, Chief Product Officer at NIQ. “Innovation is our compass, and our commitment to reengineering the Connect platform has charted a new course. Our strategic investments have allowed us to unlock the power of modern data sharing capabilities, guiding our clients towards a brighter, data-driven future."
NIQ Connect is a crucial asset for enterprises, enabling them to harness their data across all facets of their organization. With integrated data assets, businesses can readily identify emerging trends, pinpoint performance gaps, and respond swiftly to growth opportunities. This global collaboration is poised to unveil novel insights, leading to a deeper understanding of customers' behavior and preferences.
Additional highlights of the NIQ’s Connect platform integration with Snowflake’s Retail Data Cloud include:
- Seamless Data Integration: Companies will benefit from the seamless integration of NIQ's rich consumer and market data into Snowflake’s environment. This integration simplifies access to vast data sources, and drives significant speed improvements for our clients when accessing data.
- Secure Data Sharing: Availability through Snowflake facilitates near real-time data sharing, enabling businesses to access and query NIQ's data instantaneously. This dynamic exchange of information empowers organizations to stay ahead in today's fast-paced business landscape.
- Scalability and Flexibility: NIQ’s Connect platform with Snowflake Secure Data Sharing is designed to scale effortlessly with the growing data needs of businesses. Whether a company is a startup or a Fortune 500 enterprise, this provides the flexibility to adapt and grow in a rapidly changing environment.
- Enhanced AI and Machine Learning Capabilities: Businesses can leverage advanced analytics and machine learning within Snowflake's platform to derive actionable insights from NIQ's data. This synergy fosters innovation, enabling companies to make data-driven decisions with precision.
- Data Security and Compliance: Both NIQ and Snowflake prioritize data security and compliance. The joint solution ensures that sensitive data is protected providing peace of mind to businesses and their customers while enabling them to meet evolving regulatory requirements.
“NIQ is committed to helping companies become more agile at a time when being able to move quickly based on accurate data is paramount,” Treangen added. “This innovative data-sharing approach will provide Connect customers a competitive advantage today and be better prepared for the future. We are modernizing every level of our Connect platform, and we are excited about the enhancements to help our clients thrive.”
“As an incumbent leader in retail and consumer insights, NIQ has been a staple in the retail industry for delivering data that give a competitive edge to retailers and consumer product companies,” said Rosemary DeAragon, Global Head of Retail and Consumer Goods at Snowflake. “We are so excited to bring together the full power of the Snowflake Retail Data Cloud and the NIQ Connect platform, allowing global frictionless access to critical data through Snowflake data sharing.”
NIQ is dedicated to fostering innovation and enabling organizations to thrive in a data-driven world. The collaboration between NIQ and Snowflake represents a transformative step in the world of data sharing and will shape the future of data analytics. As organizations increasingly recognize the value of data in their operations, allowing them to exchange insights seamlessly and efficiently will empower them to unlock new opportunities and navigate the data landscape with ease.
For more information about this NIQ Connect and its benefits, please visit https://nielseniq.com/global/en/solutions/nielseniq-connect/.
About NIQ
NIQ is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. In 2023, NIQ combined with GfK, bringing together the two industry leaders with unparalleled global reach. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full ViewTM.
NIQ, is an Advent International portfolio company with operations in 100+ markets, covering more than 90% of the world’s population. For more information, visit NIQ.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919644465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom